NCT02521974View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children

PHASE4CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 29, 2016

Conditions
Adverse Event Following Immunisation
Interventions
BIOLOGICAL

SABIN monovalent OPV2

SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2

Sponsors

Lead Sponsor

Fidec Corporation
All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Fidec Corporation

OTHER